|
ZHEJIANG RONGYAO BIOTECH CO.,LTD.
|
Meropenem CAS 96036-03-2 is a broad-spectrum carbapenem antibiotic, which is a type of β- Lactam antibiotics are used to treat various types of infections, including meningitis and pneumonia.
Meropenem CAS 96036-03-2 is an organic compound that is an artificially synthesized broad-spectrum carbapenem antibiotic. It exerts antibacterial effects by inhibiting the synthesis of bacterial cell walls. Meropenem CAS 96036-03-2 easily penetrates the cell walls of most Gram positive and negative bacteria, achieving its target of action, penicillin binding protein (PBPS). Metal removal β- Except for lactamases, they have a significant impact on most β- The hydrolysis of lactamases (including penicillin enzymes and cephalosporin enzymes produced by Gram positive and Gram negative bacteria) has strong stability. Meropenem CAS 96036-03-2 is not suitable for the treatment of methicillin-resistant Staphylococcus infections, and sometimes exhibits cross resistance to other carbapenem resistant strains. In vitro experiments have shown that the combination of Meropenem CAS 96036-03-2 and aminoglycoside antibiotics can produce a synergistic effect on some isolated strains of Pseudomonas aeruginosa.
Meropenem CAS 96036-03-2 is suitable for the following infections in adults and children caused by single or multiple bacteria sensitive to Meropenem CAS 96036-03-2: the site of endometritis onset; Pneumonia (including hospital acquired pneumonia), urinary tract infections, gynecological infections such as endometritis and pelvic inflammatory disease, skin and soft tissue infections, meningitis, and sepsis; Empirical treatment: For adult patients with granulocytopenia and fever, this product can be used alone or in combination with antiviral or antifungal drugs.
Meropenem CAS 96036-03-2 can be used alone or in combination with other antimicrobial agents to treat multiple bacterial infections. There is currently no experience of using this product for infant patients with neutropenia or primary or secondary immunodeficiency. |
Send Inquiry
|
Pharma Sources Insight June 2024: Globalization on the Go
